Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIII 890 CL
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 73

Registration Number: NCT02269215

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of losartan
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: High dose of losartan

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 330

Registration Number: NCT02269176

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BIIL 284 BS, low dose
Drug: BIIL 284 BS, high dose
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02269189

Tolerability of Asasantin in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT02269228

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin®
Drug: Acetylsalicylic acid high dose
Drug: Acetylsalicylic acid low dose

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02268773

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Prednisone

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02268149

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIB 722 CL

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02268604

Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILN 2061 ZW single rising doses
Drug: BILN 2061 ZW fixed dose
Drug: Placebo
Other: Standardized breakfast

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT02268760

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BIII 890 CL
Drug: Placebo

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 76

Registration Number: NCT02268136

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBB 515 BS
Drug: Placebo
Drug: Pravastatin

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02266485

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy